Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?—Case Report
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rentero, D.; Juanes, A.; Losada, C.P.; Álvarez, S.; Parra, A.; Santana, V.; Martí, I.; Urricelqui, J. New-onset psychosis in COVID-19 pandemic: A case series in Madrid. Psychiatry Res. 2020, 290, 113097. [Google Scholar] [PubMed]
- Wu, Y.; Xu, X.; Chen, Z.; Duan, J.; Hashimoto, K.; Yang, L.; Liu, C.; Yang, C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav. Immun. 2020, 87, 18–22. [Google Scholar]
- Moriguchi, T.; Harii, N.; Goto, J. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 2020, 94, 55–58. [Google Scholar] [CrossRef] [PubMed]
- Mao, L.; Jin, H.; Wang, M.; Hu, Y.; Chen, S.; He, Q.; Chang, J.; Hong, C.; Zhou, Y.; Wang, D.; et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77, 683–690. [Google Scholar] [CrossRef] [Green Version]
- Zawilska, J.B.; Swaczyna, T.; Masiarek, P.; Waligórska, A.; Dominiak, Z. COVID-19: Epidemiology, pathogenesis, diagnosis and clinical symptoms. Farm. Pol. 2021, 77, 166–177. [Google Scholar] [CrossRef]
- Zhou, Z.; Zhao, N.; Shu, Y.; Han, S.; Chen, B.; Shu, X. Effect of gastrointestinal symptoms in patients with COVID-19. Gastroenterology 2020, 158, 2294. [Google Scholar] [CrossRef]
- Correa-Palacio, A.F.; Hernandez-Huerta, D.; Gómez-Arnau, J.; Loeck, C.; Caballero, I. Affective psychosis after COVID-19 infection in a previously healthy patient: A case report. Psychiatry Res. 2020, 290, 113115. [Google Scholar] [CrossRef]
- Główny Inspektorat Sanitarny: Definicja Przypadku COVID-19 na Potrzeby Nadzoru Epidemiologicznego nad Zakażeniami Wirusem SARS-CoV-2 (Definicja z 31.10.2020 r.). Available online: https://www.gov.pl/web/gis/definicja-przypadku-covid19-na-potrzeby-nadzoru-epidemiologicznego-nad-zakazeniami-wirusem-sars-cov-2-definicja-z-dnia-31102020- (accessed on 7 July 2022).
- Michalski, A.; Bielawska-Drózd, A.; Cieślik, P.; Makowski, P.; Kocik, J. Metody diagnostyki laboratoryjnej COVID-19. Wiedza Med. 2020, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Flisiak, R.; Parczewski, M.; Horban, A. Zalecenia diagnostyki i terapii zakażeń SARS-CoV-2 Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych z dnia 13 października 2020 roku. Aneks 2 do rekomendacji z 31 marca 2020 roku. Med. Prakt. 2020, 11, 51–69. [Google Scholar]
- Stanowisko Zarządu Głównego Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych w sprawie wartości diagnostycznej testów antygenowych wykorzystywanych w rozpoznawaniu zakażeń SARS-CoV-2, na dzień 14 listopada 2020 r. Available online: https://ptmr.info.pl/wp-content/uploads/2020/09/Wartosc-diagnostyczna-testow-antygenowych.pdf (accessed on 7 July 2022).
- Cieszanowski, A.; Czekajska, E.; Giżycka, B.; Gruszczyńska, K.; Podgórska, J.; Serafin, Z.; Serafin, Z.; Walecki, J. Wskazania do Wykonywania badań Obrazowych w Zakażeniach SARS-CoV-2-Zalecenia Polskiego Lekarskiego Towarzystwa Radiologicznego. Available online: https://pltr.pl/wp-content/uploads/2021/12/10.12.2021-Wskazania-do-wykonywania-badan-obrazowych-w-zakazeniach-SARS-CoV-2-1.pdf (accessed on 7 July 2022).
- Pontone, G.; Scafuri, S.; Mancini, M.E.; Agalbato, C.; Guglielmo, M.; Baggiano, A.; Muscogiuri, G.; Fusini, L.; Andreini, D.; Mushtaq, S.; et al. Role of computed tomography in COVID-19. J. Cardiovasc. Comput. Tomogr. 2021, 15, 27–36. [Google Scholar]
- Fu, F.; Lou, J.; Xi, D.; Bai, Y.; Ma, G.; Zhao, B.; Liu, D.; Bao, G.; Lei, Z.; Wang, M. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur. Radiol. 2020, 30, 5489–5498. [Google Scholar] [CrossRef]
- Wang, H.Y.; Li, X.L.; Yan, Z.R.; Sun, X.P.; Han, J.; Zhang, B.W. Potential neurological symptoms of COVID-19. Ther. Adv. Neurol. Disord. 2020, 13, 1756286420917830. [Google Scholar] [CrossRef] [Green Version]
- Valdés-Florido, M.J.; López-Díaz, A.; Palermo-Zeballos, F.J.; Martínez-Molina, I.; Martín-Gil, V.E.; Crespo-Facorro, B.; Ruiz-Veguilla, M. Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. Rev. Psiquiatr. Salud Ment. 2020, 13, 90–94. [Google Scholar] [CrossRef]
- Mancilla-Galindo, J.; Garcia-Mendez, J.O.; Marquez-Sanchez, J.; Reyes-Casarrubias, R.E.; Aguirre-Aguilar, E.; Rocha-Gonzalez, H.I.; Kammar-Garcia, A. Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study. medRxiv 2020. [Google Scholar] [CrossRef]
- Aranda-Abreu, G.E.; Aranda-Martínez, J.D.; Araújo, R.; Hernández-Aguilar, M.E.; Herrera-Covarrubias, D.; Rojas-Durán, F. Observational study of people infected with SARS-CoV-2, treated with amantadine. Pharmacol. Rep. 2020, 72, 1538–1541. [Google Scholar] [CrossRef] [PubMed]
- Rejdak, K.; Grieb, P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: Multiple sclerosis, parkinsonism and cognitive impairment. Mult. Scler. Relat Disord. 2020, 42, 102163. [Google Scholar] [CrossRef]
- Fink, K.; Nitsche, A.; Neumann, M.; Grossegesse, M.; Eisele, K.-H.; Danysz, W. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539. [Google Scholar] [CrossRef] [PubMed]
- Sęczkowska, M.; Jasiński, M. Amantadyna: Synteza, właściwości oraz aktywność wobec COVID-19. Available online: http://wpt.uni.opole.pl/wp-content/uploads/2021/11/Ksiazka-abstraktow-PSSCh.pdf (accessed on 7 July 2022).
- Smieszek, S.P.; Przychodzen, B.P.; Polymeropoulos, M.H. Amantadine disrupts lysosomal gene expression: A hypothesis for COVID-19 treatment. Int. J. Antimicrob Agents 2020, 55, 106004. [Google Scholar] [CrossRef] [PubMed]
- Sławek, J. Kliniczne znaczenie blokowania receptora NMDA. Pol. Przegląd Neurol. 2013, 9, 39–46. [Google Scholar]
- Smith, E.J. Amantadine-induced psychosis in a young healthy patient. Am. J. Psychiatry 2008, 165, 1613. [Google Scholar] [CrossRef] [PubMed]
- Blanpied, T.A.; Clarke, R.J.; Johnson, J.W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 2005, 25, 3312–3322. [Google Scholar] [CrossRef] [Green Version]
- Snoey, E.R.; Bessen, H.A. Acute psychosis after amantadine overdose. Ann. Emerg. Med. 1990, 19, 668–670. [Google Scholar] [CrossRef] [PubMed]
- Postma, J.U.; Van Tilburg, W. Visual Hallucinations and Delirium During Treatment with Amantadine (Symmetrel). J. Am. Geriatr. Soc. 1975, 23, 212–215. [Google Scholar] [CrossRef] [PubMed]
- de Roin, S.; Winters, S. Amantadine hydrochloride: Current and new uses. J. Neurosci. Nurs. 1990, 22, 322–332. [Google Scholar] [CrossRef]
- Li, Y.C.; Bai, W.Z.; Hashikawa, T. The neuroinvasive potential of SARS- CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J. Med. Virol. 2020, 92, 552–555. [Google Scholar] [CrossRef]
- Wang, L.; De Kloet, A.D.; Pati, D.; Hiller, H.; Smith, J.A.; Pioquinto, D.J.; Ludin, J.A.; Oh, S.P.; Katovich, M.J.; Frazier, C.J.; et al. Increasing brain angiotensin converting enzyme 2 activity decreases anxiety- like behavior in male mice by activating central Mas receptors. Neuropharmacology 2016, 105, 114–123. [Google Scholar] [CrossRef] [Green Version]
- Moreira, J.L.S.; Barbosa, S.M.B.; Vieira, J.G.; Chaves, N.C.B.; Felix, E.B.G.; Feitosa, P.W.G.; da Cruz, I.S.; da Silva, C.G.L.; Neto, M.L.R. The psychiatric and neuropsychiatric repercussions associated with severe infections of COVID-19 and other coronaviruses. Prog. Neuropsychopharmacol. Biol. Psychiatry 2021, 106, 110159. [Google Scholar] [CrossRef]
- Troyer, E.A.; Kohn, J.N.; Hong, S. Are we facing a crashing wave of neuropsy-chiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 2020, 87, 34–39. [Google Scholar] [CrossRef]
- Beach, S.R.; Praschan, N.C.; Hogan, C.; Dotson, S.; Merideth, F.; Kontos, N.; Fricchione, G.L.; Smith, F.A. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. Gen. Hosp. Psychiatry 2020, 65, 47–53. [Google Scholar] [CrossRef] [PubMed]
- Rogers, J.P.; Chesney, E.; Oliver, D.; Pollak, T.A.; McGuire, P.; Fusar-Poli, P.; Zandi, M.S.; Lewis, G.; David, A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020, 7, 611–627. [Google Scholar] [CrossRef]
- Dinakaran, D.; Manjunatha, N.; Kumar, C.N.; Suresh, B.M. Neuropsychiatric aspects of COVID-19 pandemic: A selective review. Asian J. Psychiatry 2020, 53, 102188. [Google Scholar] [CrossRef]
- Makara-Studzińska, M.; Załuski, M.; Lickiewicz, J. Czy ozdrowieńcy COVID-19 to przyszli pacjenci psychiatrów i psychologów? Szybki przegląd literatury naukowej. Psychiatria 2021, 18, 140–151. [Google Scholar] [CrossRef]
- Douaud, G.; Lee, S.; Alfaro-Almagro, F.; Arthofer, C.; Wang, C.; McCarthy, P.; Lange, F.; Andersson, J.L.R.; Griffanti, L.; Duff, E.; et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022, 604, 697–707. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Long, X.; Zhang, Q.; Fang, X.; Fang, F.; Lv, X.; Zhang, D.; Sun, Y.; Li, N.; Hu, S.; et al. Emerging evidence for neuropsychoconsequences of COVID-19. Curr. Neuropharmacol. 2021, 19, 92–96. [Google Scholar] [CrossRef] [PubMed]
- Taquet, M.; Luciano, S.; Geddes, J.R.; Harrison, P.J. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry 2021, 8, 130–140. [Google Scholar] [CrossRef] [PubMed]
System | Symptoms |
---|---|
respiratory | shortness of breath, runny nose, cough, changes in the sense of smell, acute respiratory disorder (ARDS), pneumonia |
cardiovascular | abnormal heart rhythm (bradyarrhythmias, tachyarrhythmias), acute heart failure, heart attack, cardiomyopathies, disseminated intravascular coagulation (DIC), thrombosis |
digestive | nausea and vomiting, loss of appetite, diarrhea, abdominal pain |
urinary | acute kidney injury (AKI), diffuse acute tubular injury, tubular necrotic changes |
reproductive | damage to the testes and ovaries, hormonal disorders, in pregnant women: perfusion disorders of the fetal blood vessels, intrauterine growth inhibition (IUGR), premature rupture fetal membrane (pPROM) and preterm labor |
skin | hives, itching, changes in the form of spots, pimples, papules, confluent rashes |
neurological | headache and dizziness, delirium syndromes, strokes (ischemic, hemorrhagic), convulsions, encephalopathies, consciousness disorders, cognitive disorders, meningitis, ZOMR, ataxia, parkinsonism, photophobia and phonophobia |
Type of Examination | Abnormalities |
---|---|
Laboratory tests | ↑ WBC, PLT, ALT, AST, urea, LDH, creatinine, CRP, PCT, ESR, D-dimers, CK-NAC ↓ WBC, lymphocytes, eosinophils, albumin |
Antigen test | positive score |
RT-PCR SARS-CoV-2 | positive score |
Anti-SARS-CoV-2 IgM coronavirus | reactive score |
Chest X-ray | interstitial pneumonia, focus of turbidity |
Chest CT scan | consolidations, compaction within the lung parenchyma, the image of “foggy/milky glass” or “snow blizzard” |
Angio-CT of pulmonary arteries | acute pulmonary embolism, changes in the lung parenchyma |
Chest ultrasound | pleural effusion, pneumonia |
echocardiography | acute heart failure in the course of acute respiratory failure |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tatar, D.; Świerzy, K.; Błachut, M.; Badura Brzoza, K. Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?—Case Report. Int. J. Environ. Res. Public Health 2022, 19, 15768. https://doi.org/10.3390/ijerph192315768
Tatar D, Świerzy K, Błachut M, Badura Brzoza K. Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?—Case Report. International Journal of Environmental Research and Public Health. 2022; 19(23):15768. https://doi.org/10.3390/ijerph192315768
Chicago/Turabian StyleTatar, Dominika, Krzysztof Świerzy, Michał Błachut, and Karina Badura Brzoza. 2022. "Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?—Case Report" International Journal of Environmental Research and Public Health 19, no. 23: 15768. https://doi.org/10.3390/ijerph192315768